Beatrix Ziekenhuis

Running trials

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· Source

• Active, not recruiting

  Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

  NCT04909684· Phase 3· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Source

• Recruiting

  DRUP trial

  NCT02925234· Phase 2· Source

• Active, not recruiting

  A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

  NCT02301286· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

  NCT03783429· Phase 4· Source